Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study.
about
Vascular disturbances in primary aldosteronism: clinical evidenceKCNJ5 mutations in the National Institutes of Health cohort of patients with primary hyperaldosteronism: an infrequent genetic cause of Conn's syndrome.Aldosterone: role in the cardiometabolic syndrome and resistant hypertensionTreatment resistant hypertension--investigation and conservative managementAldosterone-producing adenoma and other surgically correctable forms of primary aldosteronism.Predictors of resolution of hypertension after adrenalectomy in patients with aldosterone-producing adenomaThe role of TASK1 in aldosterone production and its expression in normal adrenal and aldosterone-producing adenomas.Non-interventional management of resistant hypertension.Benefits from treatment and control of patients with resistant hypertension.Resistant hypertension workup and approach to treatmentAldosteronism and resistant hypertension.Common secondary causes of resistant hypertension and rational for treatmentDiagnostic value of I-131 NP-59 SPECT/CT scintigraphy in patients with subclinical or atypical features of primary aldosteronism.Clinical approach in treatment of resistant hypertension.Treatment strategies for resistant arterial hypertension.CT mapping of the vertebral level of right adrenal veinAldosterone-to-renin ratio acts as the predictor distinguishing the primary aldosteronism from chronic kidney disease.A novel point mutation in the KCNJ5 gene causing primary hyperaldosteronism and early-onset autosomal dominant hypertension.Hypokalemia-Induced Rhabdomyolysis by Primary Aldosteronism Coexistent With Sporadic Inclusion Body Myositis.Persistent hypertension after adrenalectomy for an aldosterone-producing adenoma: weight as a critical prognostic factor for aldosterone's lasting effect on the cardiac and vascular systems.Role of Nox2 and p22phox in Persistent Postoperative Hypertension in Aldosterone-Producing Adenoma Patients after AdrenalectomyEvaluation of right adrenal vein anatomy by Dyna computed tomography in patients with primary aldosteronismPredictors of successful outcome after adrenalectomy for primary aldosteronism.Long term outcome of Aldosteronism after target treatments.Management of patients with resistant hypertension: current treatment options.Risk factors for renal impairment revealed after unilateral adrenalectomy in patients with primary aldosteronism.Different effects of progesterone and estradiol on chimeric and wild type aldosterone synthase in vitro.Non-stimulated adrenal venous sampling using Dyna computed tomography in patients with primary aldosteronismCardiac Dysfunction in Association with Increased Inflammatory Markers in Primary Aldosteronism.CACNA1H Mutations Are Associated With Different Forms of Primary Aldosteronism.Reduction of blood pressure in patients with treatment-resistant hypertension.Challenging hypertension: how to diagnose and treat resistant hypertension in daily clinical practice.Cardiovascular and renal damage in primary aldosteronism: outcomes after treatment.Primary aldosteronism: A contrarian view.Epidemiology of resistant hypertension.Primary hyperaldosteronism: expanding the diagnostic net.Spontaneous remission of idiopathic aldosteronism after long-term treatment with spironolactone: results from the German Conn's Registry.Renal denervation and treatment of hypertension.Left heart morphology and function in primary aldosteronism.The possibility of resistant hypertension during the treatment of hypertensive patients.
P2860
Q26852612-C6A07FB4-1FDC-4E85-8A9F-99B12ADFB5E1Q33698924-CF1DDD5C-00BA-4EEA-8AC0-01C8737FF603Q33736838-37805136-D9BA-40BF-9BA6-B5DDF32972F6Q33892370-8A7B4AAF-4EF3-49F3-9D85-575A539C1D7DQ33930728-6BC67694-2865-4F3B-BF79-D8BDA94CF9FFQ33935312-E0D062BF-D39A-4FA6-8A80-E5A06DC9B2B8Q34153759-2D30C235-EE70-452F-9C7B-1C4F05053D2FQ34404475-46D8449B-8E66-4DD1-A12F-D01A28562D7AQ34460638-110819CB-8D01-4844-8A38-A2CF556E5227Q34460704-41851850-6E12-4787-A7B7-C8610273A3BCQ34557307-4D077FB4-9E1B-453D-8084-758D78F7E3BEQ34669789-BA0DECAA-D5D2-4A82-AB40-9E052E209EA8Q34895778-BFBDDF0C-99CC-4EA4-8A4A-712A9A39A299Q35232666-FC3A9316-3CCB-4077-AB77-782A26238D42Q35565367-812BE3F2-0D7C-4CE8-A279-1519CA1D0EFFQ35721209-B32F631E-6D2A-4DC6-8C3D-9E08E83BEB63Q35919186-64C83CC6-A4D7-49E3-8B79-E6C6659B5E29Q36134787-FC8BD6C2-04DC-4E38-89C9-B4DEE749173EQ36302215-CCA1F267-6932-4BA0-BFFC-2323E6A773F7Q36328431-64ED70F3-2AC2-4998-961E-2E5F4D0C8A2FQ36632893-F8688C6D-8D3F-4629-A885-092CC0465FFBQ37030841-F0C8B9A3-3761-41E8-B369-FBB6FEA64E4AQ37044839-C3E1D549-58F2-4507-AFAA-03F841AFBBEFQ37227936-9DFBF1D1-2C3A-4382-8660-205C08AC793BQ37304418-B2A08159-12BF-4663-BB40-662176916236Q37327876-5BC2F2C5-7DCB-4593-929C-36F2CB72512DQ37359234-10349E24-5F48-4B6B-9E66-D12B7DE9C488Q37431094-34AD3A99-1541-4CD5-BA75-C52DF16D662EQ37541407-4AE6389A-45B9-410A-BB65-064F534EF4C1Q37604722-1A3886D3-AAD8-4964-B61A-EB1228D05EA2Q37635112-16E310D2-6187-4958-BBEB-DBE527A058FAQ37763199-9FBB7D32-7A36-4622-9B77-D39988E24CC7Q37779717-47620973-EA28-47DF-886E-5BC88914911BQ37839802-570EA416-0D6A-43CC-B408-F5B1557C4451Q37901560-9B711FB5-AA7E-4368-9846-95F5E6D94750Q37923102-5753325B-40AC-4663-8301-69C8B88B402BQ37940548-85600E08-6968-4E35-BE0F-8046E4FB844BQ38016452-6557328A-11E3-495F-A669-FA214893D316Q38016453-4FA4FF15-3507-4BE1-9073-BA1E98FF9209Q38136479-D5653CA3-30AD-48B4-AE77-293A766AE29D
P2860
Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Prevalence of primary hyperald ...... ospective observational study.
@en
Prevalence of primary hyperald ...... ospective observational study.
@nl
type
label
Prevalence of primary hyperald ...... ospective observational study.
@en
Prevalence of primary hyperald ...... ospective observational study.
@nl
prefLabel
Prevalence of primary hyperald ...... ospective observational study.
@en
Prevalence of primary hyperald ...... ospective observational study.
@nl
P2093
P1433
P1476
Prevalence of primary hyperald ...... ospective observational study.
@en
P2093
Areti Triantafyllou
Chrysanthos Zamboulis
Konstantinos Petidis
Konstantinos Vogiatzis
Michael Doumas
Niki Kartali
Nikolaos Papadopoulos
Panagiota Papaefthimiou
Stella Douma
P304
P356
10.1016/S0140-6736(08)60834-X
P407
P577
2008-06-01T00:00:00Z